Literature DB >> 22872761

Regulation of the androgen receptor by post-translational modifications.

Kelly Coffey1, Craig N Robson.   

Abstract

The androgen receptor (AR) is a key molecule in prostate cancer and Kennedy's disease. Understanding the regulatory mechanisms of this steroid receptor is important in the development of potential therapies for these diseases. One layer of AR regulation is provided by post-translational modifications including phosphorylation, acetylation, sumoylation, ubiquitination and methylation. While these modifications have mostly been studied as individual events, it is becoming clear that these modifications can functionally interact with each other in a signalling pathway. In this review, the effects of all modifications are described with a focus on interplay between them and the functional consequences for the AR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22872761     DOI: 10.1530/JOE-12-0238

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  55 in total

1.  Effect of estrogen-active compounds on the expression of RACK1 and immunological implications.

Authors:  Erica Buoso; Mirco Masi; Valentina Galbiati; Ambra Maddalon; Martina Iulini; Maša Kenda; Marija Sollner Dolenc; Marina Marinovich; Marco Racchi; Emanuela Corsini
Journal:  Arch Toxicol       Date:  2020-04-23       Impact factor: 5.153

Review 2.  Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Authors:  Kathryn E Ware; Mariano A Garcia-Blanco; Andrew J Armstrong; Scott M Dehm
Journal:  Endocr Relat Cancer       Date:  2014-05-23       Impact factor: 5.678

3.  The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin.

Authors:  Shu-Ting Chen; Maiko Okada; Ryuichiro Nakato; Kosuke Izumi; Masashige Bando; Katsuhiko Shirahige
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

4.  Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats.

Authors:  Young Mi Seok; Hae Ahm Lee; Kwon Moo Park; Mi-Hyang Hwangbo; In Kyeom Kim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-22       Impact factor: 3.000

Review 5.  Androgen pathway resistance in prostate cancer and therapeutic implications.

Authors:  Benjamin L Maughan; Emmanuel S Antonarakis
Journal:  Expert Opin Pharmacother       Date:  2015-06-12       Impact factor: 3.889

Review 6.  Implications of ubiquitin ligases in castration-resistant prostate cancer.

Authors:  Jianfei Qi; Lingling Fan; Arif Hussain
Journal:  Curr Opin Oncol       Date:  2015-05       Impact factor: 3.645

Review 7.  Contemporary agents in the management of metastatic castration-resistant prostate cancer.

Authors:  Anil Kapoor; Christopher Wu; Bobby Shayegan; Adrian P Rybak
Journal:  Can Urol Assoc J       Date:  2016-12-12       Impact factor: 1.862

8.  Relationship between serum response factor and androgen receptor in prostate cancer.

Authors:  Maria Prencipe; Amanda O'Neill; Gillian O'Hurley; Lan K Nguyen; Aurelie Fabre; Anders Bjartell; William M Gallagher; Colm Morrissey; Elaine W Kay; R William Watson
Journal:  Prostate       Date:  2015-08-07       Impact factor: 4.104

9.  USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.

Authors:  Randy S Schrecengost; Jeffry L Dean; Jonathan F Goodwin; Matthew J Schiewer; Mark W Urban; Timothy J Stanek; Robyn T Sussman; Jessica L Hicks; Ruth C Birbe; Rossitza A Draganova-Tacheva; Tapio Visakorpi; Angelo M DeMarzo; Steven B McMahon; Karen E Knudsen
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

10.  The von hippel-lindau protein suppresses androgen receptor activity.

Authors:  Jing Wang; Wei Zhang; Wei Ji; Xing Liu; Gang Ouyang; Wuhan Xiao
Journal:  Mol Endocrinol       Date:  2014-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.